Public pharmaceutical companies leverage RNA Advisors for assistance with M&A opportunities, out licensing of assets, royalty stream evaluations, and strategic partnership decision making. Public or mid-cap biopharma companies seek advisory support from the RNA team for life sciences investments and acquisitions (on the buy-side) as well as analytical and strategic support for due diligence, tax and financial reporting, and decision- making advice around license and asset acquisitions.
“The RNA team is responsive and efficient and understands the nuances of valuation as pertains to our sector, and we valued our partnership with them.”
“The RNA team has been incredibly professional, very responsive to our on-going and sometimes tight turnaround valuation requests and has been an absolute pleasure to work with.”
“The RNA team helped us from inception through our IPO and beyond. They are one of the top firms that I know of at the intersection of valuation, biotech and finance. I’d recommend them for my life science venture-backed company colleagues.”
Enter your email address below to receive updates from RNA Advisors.